PT  - JOURNAL ARTICLE
AU  - Ryszard Olinski
AU  - Pawel Jaruga
AU  - Marek Foksinski
AU  - Karol Bialkowski
AU  - Jerzy Tujakowski
TI  - Epirubicin-Induced Oxidative DNA Damage and Evidence for Its Repair in Lymphocytes of Cancer Patients Who Are Undergoing Chemotherapy
AID  - 10.1124/mol.52.5.882
DP  - 1997 Nov 01
TA  - Molecular Pharmacology
PG  - 882--885
VI  - 52
IP  - 5
4099  - http://molpharm.aspetjournals.org/content/52/5/882.short
4100  - http://molpharm.aspetjournals.org/content/52/5/882.full
SO  - Mol Pharmacol1997 Nov 01; 52
AB  - Anthracycline derivatives have been widely used in the treatment of several types of human malignancies. Cytotoxicity of these drugs has been attributed to inhibition of topoisomerase II as well as intracellular production of free radicals. In our work we used a gas chromatography/mass spectrometry technique to study free radical-induced DNA base modifications in chromatin isolated from lymphocytes of cancer patients who received chemotherapy with epirubicin (one of anthracycline’s antitumor derivatives). The anticancer therapy caused significant increases in the amount of all four DNA base modifications over control levels in the lymphocytes of most of the patients. For the majority of the cases the base products returned to the control value 24 hr after the infusion of the drug, which suggests the removal of these lesions by cellular repair processes. However, some of the modified bases escaped repair. Because part of these modifications may possess premutagenic properties, they may be responsible for secondary cancers induced by chemotherapy.